Search Results for: Clinical Roundup
-
Ariad Pads Cash with $300M For Iclusig Launch, Clinic Work
The infusion of an additional $300 million, however, will "go a long way for us to support the global launch of Iclusig," as well as advancing additional clinical programs, said Maria Cantor, Ariad's senior vice president of corporate affairs...A full readout from the pivotal PACE study was presented at the American Society of Clinical Oncology meeting in June, with data showing that 54 percent of chronic-phase CML patients showed a response, besting what had been reported previously in top-lineBy Jennifer Boggs | BioWorld Today | Friday, January 25, 2013 -
Clinic Roundup
Tasimelteon-treated patients maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of nighttime sleep, daytime naps and timing of sleepBioWorld Today | Thursday, January 24, 2013 -
House Vote Has Makers of MCMs Breathing a Little Easier
NIH Clinical Trial News...The trial will test multiple doses of cyclodextrin in nine patients to identify a safe dose for a Phase II multicenter trial.By Mari Serebrov | BioWorld Today | Thursday, January 24, 2013 -
Gene Signal Raises New Cash for Its Antisense Drug Trials
Gross proceeds totaled about $34.1 million and will be used for general corporate purposes, including clinical trial, preclinical and other R&D expenses, capital expenditures, working capital and general and administrative costs...Citigroup and Leerink Swann acted as joint book-running managers, while Baird acted as co-lead manager. (See BioWorld Today, Jan. 22, 2013.)By Cormac Sheridan | BioWorld Today | Thursday, January 24, 2013 -
Clinic Roundup
Ampio plans to start enrolling in a 450-patient clinical trial this quarter...Those data completed the pivotal pharmacokinetic and clinical program for BNX, which BDSI said will enable a new drug application submission in mid-2013...Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said it received approval for clinical studies from Chinese regulators to test Benapenem, a carbapenem drug in the class of broad-spectrum beta-lactam antibiotics, with a Phase I program set to start in the firstBioWorld Today | Wednesday, January 23, 2013 -
Back in 'Control': Tivo Data Explained; AVEO Bags $50M
Specifically, OS showed somewhat greater in the control arm than in the tivozanib arm. (See BioWorld Today, Jan. 4, 2012, and Aug. 6, 2012.) The OS glitch is "something that we have addressed with the FDA," Johnston said, and AVEO will be presenting more OS data at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in Orlando, Fla., next month, along with some data from subpopulations...Clinical Cancer Research included a paper that suggested the compound, ENMD-2076, actsBy Randy Osborne | BioWorld Today | Friday, January 18, 2013 -
Clinic Roundup
Cytos Biotechnology Ltd., of Zurich, Switzerland, said a technical issue was identified with the rubber stoppers used to close the injection vials containing clinical trial material for its Phase IIb study testing lead candidate CYT003 in allergic asthma...Cytos will replace that material with new material available at clinical sites in the second quarterBioWorld Today | Thursday, January 17, 2013 -
Versartis' $25M Series C to Fund HGH Trial in Children
Versartis Inc., of Redwood City, Calif., closed a $25 million Series C financing round through Aisling Capital, Index Ventures, New Leaf Venture Partners and Advent Venture Partners to support clinical trials of VRS-317 for growth hormone deficiency in children...Proceeds will be used for general corporate purposes, ultimately focused on advancing the firm's clinical pipeline...Goldman, Sachs and Co., and J.P. Morgan Securities LLC are joint book-running managers for the offerings, which will be filedBy Catherine Shaffer | BioWorld Today | Wednesday, January 16, 2013 -
FDA Begins Blazing Narrow Trail for Approval Shortcut
The proposed trail is intended to cut through the undergrowth of current clinical trial requirements by allowing for smaller, more targeted studies that wouldn't take as long to complete...Clinical trials represent an aggregate expense of about $31.3 billion, or nearly 40 percent of the R&D budget of major drug developers – much of that due to systemic inefficiency, according to the report...It's hoped that the results will help guide decisions in the future on whether a drug warrants further clinicalBy Mari Serebrov | BioWorld Today | Tuesday, January 15, 2013 -
Aileron $12M Raise to Propel Stapled Peptide into Clinic
Together, the three collaborated in the seminal discovery of the first biologically active stapled peptide and translation into a potential clinical application...Proceeds from any offering are expected to support general corporate purposes, including to R&D costs, payment obligations and capital expenditures.By Marie Powers | BioWorld Today | Tuesday, January 15, 2013 -
Clinic Roundup
BioTime Inc., of Alameda, Calif., said it submitted a clinical investigation protocol to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platformBioWorld Today | Friday, January 11, 2013 -
Financings Roundup
Proceeds will help the firm continue to expand commercial operations and clinical trials, scale laboratory capabilities and develop additional genomic profiling and information services...Foundation, which closed the initial $42.5 million in its Series B in September, is working on a genomic assay for all solid tumors that analyzes tumor DNA to help doctors match patients with targeted drugs or clinical trials best suited to their cancers. (See BioWorld Today, Sept. 20, 2012BioWorld Today | Wednesday, January 9, 2013 -
Clinic Roundup
Secondary endpoints also were met, including the clinical cure rate at end of treatment day 10 to day 14 (88.9 percent) and test of cure at day 21 to day 28 (100 percent...That allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the trial...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmissionBioWorld Today | Tuesday, January 8, 2013 -
ISA Moving HPV Vaccine into Phase II with $10.5M Round
In the VIN trial, there was a correlation between immune response and clinical response, as measured by reduction or resolution of vulvar lesions...For us it was a very good clinical proof of concept," Mark Krul, the company's other joint managing director told BioWorld Today...The company intends to use the proceeds to continue the clinical development of its immunotherapy platform, a personalized combination of cancer cell vaccination and "killer" T-cell treatmentBy Cormac Sheridan | BioWorld Today | Tuesday, January 8, 2013 -
Clinic Roundup
Durata said the secondary endpoint of clinical success at the end of treatment – the expected primary endpoint for regulatory review in Europe – also was met...NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said the first patients have been enrolled in India into its global Phase IIb BAYnovation clinical study, investigating NVC-422 ophthalmic solution as a treatment of adenoviral conjunctivitis, a highly contagious form of "pink eye" for which there is an unmet ocular medical need...The resultsBioWorld Today | Monday, January 7, 2013 -
Clinic Roundup
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., filed a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency to initiate a Phase I study of ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR), in TTR-mediated amyloidosis...ALN-TTRsc is the first GalNAc-siRNA to enter clinical development...The authors based their conclusions on post-hoc analyses of clinical data from a 1,040-patient DNA substudy of ARCA's Phase III Beta-Blocker Evaluation of SurvivalBioWorld Today | Friday, January 4, 2013 -
Financings Roundup
clinical development of the company's lead candidate, perhexiline, for the treatment of heart failure symptoms in patients with hypertrophic cardiomyopathy (HCM), an inherited heart muscle defect that leads to disordered cardiac energy metabolism, enlarged heart muscle, obstructed blood flow from the heart and eventual heart failureBioWorld Today | Friday, January 4, 2013 -
FANG Bites Off $24M Series B; Gradalis Ovarian Trial Advances
Funds from the Series B, which the firm was expected to disclose today, also will be used to progress clinical and preclinical development of its bifunctional short hairpin RNA (shRNA) platform, but it was FANG that loosened the purse strings in the round...acted as exclusive placement agent.By Randy Osborne | BioWorld Today | Thursday, January 3, 2013 -
Financings Roundup
Funds will be used for working capital and for continuation of clinical research and development of Cavatak, an oncolytic virus candidateBioWorld Today | Wednesday, December 26, 2012 -
Clinic Roundup
OMP-52M51 is OncoMed's fifth product candidate to enter clinical development, a proprietary monoclonal antibody that targets the Notch1 receptorBioWorld Today | Wednesday, December 26, 2012
Category
Current Filters
- xNOT BioWorld International
Related Keywords
Categories
- x BioWorld Today (2573)
- x Bio Perspectives (4)
- x BioWorld Insight (2)
- x State of the Industry Report (2)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.